Evolution of biomarker qualification at the health authorities

By streamlining the qualification process for biomarkers, coordinated protocols recently implemented at the different regulatory agencies can facilitate progress and provide impetus to novel biomarker discovery and validation.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    European Agency for the Evaluation of Medical Products. Public Statement: EU–US FDA Bilateral Agreement (EMEA, London, UK, 2003; accessed 8 September 2009). http://www.emea.europa.eu/pdfs/general/direct/pr/2447803en.pdf

  2. 2

    The Food and Drug Administration. Guidance for Industry: Pharmacogenomic Data Submissions (FDA, Rockville, Maryland, USA, March 2005; accessed 8 September 2009). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm079849.pdf

  3. 3

    European Agency for the Evaluation of Medical Products. Medicines and Emerging Science (EMEA, London, UK, accessed 8 September 2009) http://www.emea.europa.eu/htms/human/mes/emergingtechnologies.htm

  4. 4

    The Food and Drug Administration. Fed. Reg. 69, 48876–48877 (2004). http://www.fda.gov/OHRMS/DOCKETS/98fr/04-18360.htm

  5. 5

    The European Medicines Agency. EMEA/CHMP/PGxWP/20227/04 Guideline on Pharmacognetics Briefing Meetings (EMEA, London, UK, 2004; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/pharmacogenetics/2022704en.pdf

  6. 6

    Uyama, Y. Nippon Yakurigaku Zasshi 126, 432–435 (2005).

  7. 7

    The Food and Drug Administration. Critical Path Initiative (FDA, Rockville, Maryland, USA, (2004) http://www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/default.htm

  8. 8

    The European Medicines Agency. The European Medicines Agency Road Map to 2015: Preparing the Ground for the Future (EMEA, London, UK, 2010; 8 September 2009). http://www.emea.europa.eu/htms/general/direct/roadmap/roadmapintro.htm

  9. 9

    The European Medicines Agency. Innovative Drug Development Approaches (EMEA/127318/2007)—Final Report of the EMEA/CHMP Think-Tank on Innovative Drug Development (EMEA, London, UK, 2007; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/itf/12731807en.pdf

  10. 10

    Goodsaid, F.M., Frueh, F.W. & Mattes, W. Toxicology. 245, 219–223 (2008).

  11. 11

    Hunter, A.J. Drug Discov. Today. 13, 371–373 (2008).

  12. 12

    The European Medicines Agency. Final Report on the Pilot Joint EMEA/FDA VXDS Experience on Qualification of Nephrotoxicity Biomarkers (EMEA, London, UK, May 2008; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/biomarkers/25088508en.pdf

  13. 13

    Altar, C.A. et al. Clin. Pharmacol. Ther. 83, 368–371 (2008).

  14. 14

    Lathia, C.D. et al. Clin. Pharmacol. Ther. 86, 32–43 (2009).

  15. 15

    The Food and Drug Administration. E16 Genomic Biomarkers Related to Drug Response: Context, Structure, and Format of Qualification Submissions (FDA, Rockville, Maryland, USA; accessed 8 September 2009). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174433.pdf

  16. 16

    The Food and Drug Administration. Fed. Reg. 69, 42060–42061 (2004; accessed 8 September 2009). http://www.fda.gov/OHRMS/DOCKETS/98fr/04-15935.htm

  17. 17

    The Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels (FDA, Rockville, Maryland, USA; accessed 8 September 2009). http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm.

  18. 18

    The European Medicines Agency. Guidance Document on the Qualification of Novel Methodologies for Drug Development (EMEA, London, UK, January 2009; accessed 8 September 2009). http://www.ema.europa.eu/pdfs/human/biomarkers/7289408en.pdf

Download references

Author information

Correspondence to Federico Goodsaid or Marisa Papaluca.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Goodsaid, F., Papaluca, M. Evolution of biomarker qualification at the health authorities. Nat Biotechnol 28, 441–443 (2010) doi:10.1038/nbt0510-441

Download citation

Further reading